Home > Journals > Urology, Nephrology and Andrology International

Urology, Nephrology and Andrology International

Submit your article Read this Journals View all journals
Full Text (PDF)
Original Article

Is Combination Therapy (Mirabegron + Solifenacin) better than Monotherapy (Solifenacin) in the Treatment of OAB?

Sangle Ameya Rangnath , SML Prakash Babu1 , Abhishek Kulkarni2 , Sangle Ameya Rangnath3

Author Information

Licence:



Urology, Nephrology and Andrology International 7(1):p 7-13, January-June 2022. | DOI: http://dx.doi.org/10.21088/unai.2456-5016.7122.1

How Cite This Article:

SML Prakash Babu, Abhishek Kulkarni, Sangle Ameya Rangnath/Is combination therapy (Mirabegron + Solifenacin)
better than monotherapy (Solifenacin) in the treatment of OAB?/Urology, Nephrology and Andrology International
2022; 7(1):7–13
 

Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

OAB is a common and distressing chronic bladder condition presenting
with symptoms of urinary frequency, urgency, and urge incontinence.
Pharmacotherapy with antimuscarinic agents is one of the major treatment
options for OAB. Mirabegron in combination with antimuscarinic drugs is being
used for treatment-resistant OAB. Given that the two groups have different
modes of action, it is logical to think that combination therapy would have
advantages over monotherapy
 

References

No records found.


About this article

Cite this article

SML Prakash Babu, Abhishek Kulkarni, Sangle Ameya Rangnath/Is combination therapy (Mirabegron + Solifenacin)
better than monotherapy (Solifenacin) in the treatment of OAB?/Urology, Nephrology and Andrology International
2022; 7(1):7–13
 

Licence:



Received Accepted Published
N/A N/A N/A
DOI: http://dx.doi.org/10.21088/unai.2456-5016.7122.1

Keywords


Article Level Metrics

Last Updated

Thursday 30 July 2026, 04:08:18 (IST)

500

Accesses

3
140
00

Citations


NA
NA
NA

Download citation


Article Keywords

Keyword Highlighting

Highlight selected keywords in the article text.


Timeline

Received N/A
Accepted N/A
Published N/A

licence




Access this article

Reprint Order Form
Buy this Article
Institutional Subscriptions

Share